An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

CORY RAWSON LOCAL SCHOOL DISTRICT MEDIA RELEASE__The following Honor Roll has been announced by Cory-Rawson High School for ...

Madison Investments, an investment advisor, released its “Madison Sustainable Equity Strategy” first quarter 2025 investor ...

UBS is holding firm on its Buy rating and $1,050 price target for Eli Lilly, driven by faith in the upcoming SURPASS-CVOT ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Business Model Mastery’s Substack. In this article, we will ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

Banner added that the company is doing an internal and external ... as VP of comms at Roche Diagnostics during the height of the COVID-19 pandemic. In Q1, Eli Lilly posted revenue of $12.7 billion, up ...

Eli Lilly and Company (LLY)’s share was trading ... Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap in a single day. "We think the market ...